Regulation of nitrogen monoxide production in human malaria

Redox Report

Volumn 8, Issue 5, 2003, Pages 289-291

  Kun, Jürgen F J ^a  

^a UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INDUCIBLE NITRIC OXIDE SYNTHASE; NITRIC OXIDE; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR AP 1;

ANTIMICROBIAL ACTIVITY; ARTICLE; BACTERIUM; BINDING SITE; GENE CONTROL; GENE IDENTIFICATION; GENETIC VARIABILITY; HOST PATHOGEN INTERACTION; HOST RESISTANCE; HUMAN; IMMUNE RESPONSE; IMMUNE SYSTEM; IN VITRO STUDY; MALARIA; PRIORITY JOURNAL; PROTEIN FAMILY; PROTEIN FUNCTION; PROTOZOON; TRANSCRIPTION REGULATION;

ANIMALS; HUMANS; MALARIA, FALCIPARUM; NF-KAPPA B; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; NITRIC OXIDE SYNTHASE TYPE II; PLASMODIUM FALCIPARUM;

BACTERIA (MICROORGANISMS); PROTOZOA;

EID: 0347595751     PISSN: 13510002     EISSN: None     Source Type: Journal    
DOI: 10.1179/135100003225002925     Document Type: Article

References (26)

1. Bogdan C, Rollinghoff M, Diefenbach A. The role of nitric oxide in innate immunity. Immunol Rev 2000; 173: 17-26.
2. Rockett KA, Awburn MM, Cowden WB, Clark IA. Killing of Plasmodium falciparum in vitro by nitric oxide derivatives. Infect Immun 1991; 59: 3280-3283.
3. De Caterina R, Libby P, Peng HB et al. Nitric oxide decreases cytokine-induced endothelial activation. Nitric oxide selectively reduces endothelial expression of adhesion molecules and proinflammatory cytokines. J Clin Invest 1995; 96: 60-68.
4. Grau GE, Taylor TE, Molyneux ME et al. Tumor necrosis factor and disease severity in children with falciparum malaria. N Engl J Med 1989; 320: 1586-1591.
5. Florquin S, Amraoui Z, Dubois C, Decuyper J, Goldman M. The protective role of endogenously synthesized nitric oxide in staphylococcal enterotoxin B-induced shock in mice. J Exp Med 1994; 180: 1153-1158.
6. Chartrain NA, Geller DA, Koty PP et al. Molecular cloning, structure, and chromosomal localization of the human inducible nitric oxide synthase gene. J Biol Chem 1994; 269: 6765-6772.
7. Xu W, Charles IG, Liu L, Moncada S, Emson P. Molecular cloning and structural organization of the human inducible nitric oxide synthase gene (NOS2). Biochem Biophys Res Commun 1996; 219: 784-788.
8. Bredt DS, Hwang PM, Glatt CE et al. Cloned and expressed nitric oxide synthase structurally resembles cytochrome P-450 reductase. Nature 1991; 351: 714-718.
9. Geller DA, Nüssler AK, Di Silvio M et al. Cytokines, endotoxin, and glucocorticoids regulate the expression of inducible nitric oxide synthase in hepatocytes. Proc Natl Acad Sci USA 1993; 90: 522-526.
10. Nüssler AK, Di Silvio M, Billiar TR et al. Stimulation of the nitric oxide synthase pathway in human hepatocytes by cytokines and endotoxin. J Exp Med 1992; 176: 261-264.
11. Spitsin SV, Koprowski H, Michaels FH. Characterization and functional analysis of the human inducible nitric oxide synthase gene promoter. Mol Med 1996; 2: 226-235.
12. Nunokawa Y, Ishida N, Tanaka S. Promoter analysis of human inducible nitric oxide synthase gene associated with cardiovascular homeostasis. Biochem Biophys Res Commun 1994; 200: 802-807.
13. Feng X, Guo Z, Nourbakhsh M et al. Identification of a negative response element in the human inducible nitric-oxide synthase (hiNOS) promoter: the role of NF-kappa B-repressing factor (NRF) in basal repression of the hiNOS gene. Proc Natl Acad Sci USA 2002; 99: 14212-14217.
14. Ganster RW, Taylor BS, Shao L, Geller DA. Complex regulation of human inducible nitric oxide synthase gene transcription by Stat 1 and NF-kappa B. Proc Natl Acad Sci USA 2001; 98: 8638-8643.
15. Taylor BS, de Vera ME, Ganster RW et al. Multiple NF-kappaB enhancer elements regulate cytokine induction of the human inducible nitric oxide synthase gene. J Biol Chem 1998; 273: 15148-15156.
16. Marks-Konczalik J, Chu SC, Moss J. Cytokine-mediated transcriptional induction of the human inducible nitric oxide synthase gene requires both activator protein 1 and nuclear factor kappaB-binding sites. J Biol Chem 1998; 273: 22201-22208.
17. Morris BJ, Markus A, Glenn CL. et al. Association of a functional inducible nitric oxide synthase promoter variant with complications in type 2 diabetes. J Mol Med 2002; 80: 96-104.
18. Warpeha KM, Xu W, Liu L et al. Genotyping and functional analysis of a polymorphic (CCTTT)(n) repeat of NOS2A in diabetic retinopathy. FASEB J 1999; 13: 1825-1832.
19. Burgner D, Xu W, Rockett K et al. Inducible nitric oxide synthase polymorphism and fatal cerebral malaria. Lancet 1998; 352: 1193-1194.
20. Burgner D, Usen S, Rockett K et al. Nucleotide and haplotypic diversity of the NOS2A promoter region and its relationship to cerebral malaria. Hum Genet 2003; (electronically published ahead of print).
21. Ohashi J, Naka I, Patarapotikul J et al. Significant association of longer forms of CCTTT Microsatellite repeat in the inducible nitric oxide synthase promoter with severe malaria in Thailand. J Infect Dis 2002; 186: 578-581.
22. Kun JFJ, Mordmüller B, Lell B et al. Polymorphism in the promoter region of the inducible nitric oxide synthase gene and protection against malaria. Lancet 1998; 351: 265-266.
23. ńe (G-954C), increased nitric oxide production and protection against malaria. J Infect Dis 2001; 184: 330-336.
24. Hobbs MR, Udhayakumar V, Levesque MC et al. A new NOS2 promoter polymorphism associated with increased nitric oxide production and protection from severe malaria in Tanzanian and Kenyan children. Lancet 2002; 360: 1468-1475.
25. Pance A, Chantome A, Reveneau S, Bentrari F, Jeannin JF. A repressor in the proximal human inducible nitric oxide synthase promoter modulates transcriptional activation. FASEB J 2002; 16: 631-633.
26. Lopansri BK, Anstey NM, Weinberg JB et al. Low plasma arginine concentrations in children with cerebral malaria and decreased nitric oxide production. Lancet 2003; 361: 676-678